Adaptimmune, a biotech company founded in 2008, has made significant strides in developing T-cell receptor (TCR)-T therapies for cancer. Despite challenges and rocky collaborations with pharmaceutical giants like GSK and Astellas, Adaptimmune achieved a major breakthrough with the FDA approval of its first engineered TCR-T therapy, afami-cel, for treating metastatic or unresectable synovial sarcoma. This approval marks several firsts in the field of cell therapy, offering new hope for patients with rare solid tumors.
